University of Birmingham's cancer immunotherapy developer Revitope Oncology secured equity funding as part of a $160m alliance with Junshi Biosciences.
Revitope Oncology, a US-based cancer therapeutics spinout of University of Birmingham, is set to receive $10m in equity funding from biopharmaceutical firm Junshi Biosciences as part of a collaboration and licensing agreement. Junshi could supply as much as $160m for each molecule discovered under the partnership in milestones and royalties. Ā The equity funding is in…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
